German Biotechnology Firm Increases Monoclonal Antibody Capability
By Biotechdaily staff writers
Posted on 31 Jul 2007
A major European biopharmaceuticals manufacturer has announced the imminent completion of the expansion of its facility for production of therapeutic proteins and monoclonal antibodies.Posted on 31 Jul 2007
Rentschler Biotechnologie (Laupheim, Germany), an international full-service contract manufacturer with more than 30 years of experience in the development, production, and approval of biopharmaceuticals, has announced the mid-2008 completion of two new 2,500 L multi-process fermentation suites. Each suite comprises five 500 L fermenter lines. The expansion project as a whole includes a new laboratory building, a central energy station, and a logistics space as well as additional facilities for sterile filling of syringes and injection vials.
In addition to process development and production, including formulation and fill and finish, Rentshcler offers add-on services such as assistance in drug registration and formulation development.
Related Links:
Rentschler Biotechnologie
Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
